Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause
Standfirst: A hospitalised patient with a Hy’s-law-like profile has forced
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Late on Monday night in California — 10:30 p.m. PT
The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech
Lila’s Nvidia-backed raise is about more than money. It is
AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity
AstraZeneca has inked a deal worth “up to” $555 million
Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
Pfizer has rejoined the weight-loss race with a $4.9bn move
Dermatology’s next play: bispecifics that shut down OX40L and TNF
Pairing a T-cell co-stimulatory brake with an inflammatory workhorse is
Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030?
Beyond CRISPR Hype Gene editing has promised to revolutionize medicine,
The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer
Madrid has put blood pressure back on the biotech map.
The patch that could unstick vaccination: Vaxxas’s A$90m bet on needle-free delivery
Brisbane-based Vaxxas has raised ~A$90m (A$49.22m Series D equity plus
From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals
When Dr. Vinay Prasad was abruptly removed from his FDA
From Platform to Precision: The $800M Bet Transforming Biotech Investing
Inside TCG Labs Soleil’s $400M Bet on Focused Biotech On
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
In the high-stakes world of biotechnology, big pharma acquisitions often
EU’s €12.5M Bet on Oncomatryx and Antibody-Drug Conjugates (ADCs)
European biotech received a confidence boost as the EU’s European
Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution
CRISPRware Signals a New Era in Democratized Gene Editing In
Texas Ban on Lab-Grown Meat Triggers Policy and Legal Showdowns
A State-Level Ban in the Lone Star State In a
From Early Detection to Tumor “Education”: Syantra’s Bold Bet on cfRNA in Cancer Tech
A New Direction in Liquid Biopsy When Syantra Inc. announced
€132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital?
Europe’s biotech ecosystem just notched a headline-grabbing win. Azafaros, a
From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough
In a biotech landscape often preoccupied with the elusive fountain
Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy
By investing $80 million to transform a small California fermentation
Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity
In a world obsessed with youth, some scientists are turning
Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market
High cholesterol has long been a silent threat lurking in
Beijing’s Biotech Blitz Is Outpacing America. Washington Needs a War Plan.
For decades, the United States has led the world in
A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads
When Dr. Peter Marks walked out of the FDA’s headquarters
From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle
Layoffs Hit Biotech Hubs Hard In labs from Boston’s Kendall
